View Clinical Trial (Medical Research Study)
CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
| City: |
|
Kingsport |
| State: |
|
Tennessee |
| Zip Code: |
|
37660 |
| Conditions: |
|
Coronary Artery Disease - Coronary Disease - Myocardial Ischemia - Heart Diseases - Cardiovascular Diseases - Arteriosclerosis - Arterial Occlusive Diseases - Vascular Diseases |
| Purpose: |
|
The objective of this study is to evaluate the safety and effectiveness of the clinical and
technical performance of the CorPath® 200 System in the delivery and manipulation of
coronary guidewires and stent/balloon systems for use in percutaneous coronary interventions
(PCI).
|
| Study Summary: |
|
|
| Criteria: |
|
General Inclusion Criteria:
1. Subject is between 18 and 99 years of age.
2. Subject is an acceptable candidate for PCI.
3. Subject must have clinical evidence of ischemic heart disease or a positive
functional study.
4. Female subjects must be of non-child bearing potential, or if able to bear children,
have a negative pregnancy test within 7 days prior to the CorPath procedure.
5. The subject or the legal representative has been informed of the nature of the study
and agrees to its provisions and has provided written informed consent.
Angiographic Inclusion Criteria:
1. Study lesion is a single de novo native coronary artery lesion. This lesion may
consist of multiple lesions (with 10mm or less between diseased segments) and must be
completely covered by a single stent with at least 2.0mm of normal segments on
proximal and distal edges of the lesion.
2. Study reference vessel diameter is between 2.5mm and 4.0mm by visual estimate.
3. Study lesion length is less than or equal to 24.0mm by visual estimate.
4. Study lesion diameter showing stenosis of at least 50% by visual estimate.
General Exclusion Criteria:
1. Subject requires planned PCI or CABG (Coronary Artery Bypass Graft) within 30 days
following the CorPath procedure.
2. Evidence of an acute myocardial infarction within 72 hours prior to the intended
CorPath procedure.
3. Subject has documented left ventricular ejection fraction <30%.
4. Subject has undergone PCI within 72 hours prior to the CorPath procedure.
5. Subject has undergone PCI within 30 days prior to the CorPath procedure and
experienced a major adverse coronary event (MACE) or a serious adverse event (SAE) as
defined in the protocol.
6. Subject has known hypersensitivity or contraindication to aspirin, heparin,
ticlopidine, clopidogrel, prasugrel, stainless steel, cobalt chromium, or sensitivity
to contrast media, including Visipaque™, which cannot be adequately pre-medicated or
managed with clinically appropriate substitutes.
7. Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, or a WBC count
of <3,000 cells/mm3 (e.g. thrombocytopenia, thrombocythemia, neutropenia or
leukopenia).
8. Subject has a serum creatinine level of >2.0 mg/dL or eGFR <30 ml/min as measured
within 7 days prior to the procedure.
9. Subject has suffered a stroke within 30 days prior to planned CorPath procedure.
10. Subject has an active peptic ulcer or upper gastrointestinal bleeding within the 6
months prior to planned CorPath procedure.
11. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
transfusions.
12. Subject is currently participating in another investigational drug or drug/device or
device trial and has not completed the entire follow up period.
13. Femoral access is not possible.
Angiographic Exclusion Criteria:
1. Target lesion that cannot be fully covered by a single stent.
2. Subject requires treatment of more than one vessel.
3. Any previous stent placement within 5.0 mm (proximal or distal) of the target lesion.
4. The study lesion requires planned treatment with directional coronary atherectomy
(DCA), laser, rotational atherectomy or any device except for balloon dilatation
prior to stent placement.
5. The study vessel has evidence of intraluminal thrombus.
6. The study vessel has evidence of moderate to severe tortuosity (>90°) proximal to the
target lesion.
7. The study lesion has any of the following characteristics:
- Total occlusion.
- Ostial location.
- Is within 2.0 mm of a side branch measuring >2.0 mm in diameter.
- Located at < 45° bend in the vessel.
- Moderately to severely calcified.
- Moderate to severe calcification in the vessel proximal to the target lesion.
- Located in a native vessel distal to an anastomosis, with a saphenous vein graft
or a left/right internal mammary artery (LIMA/RIMA) bypass, and is approached
through the bypass graft.
8. Unprotected left main coronary artery disease defined as an obstruction greater than
50% diameter stenosis in the left main coronary artery.
|
| NCT ID: |
|
NCT01275092 |
| Primary Contact: |
|
Study Director
Michail Pankratov, MD/PhD
Corindus Inc.
Michail Pankratov, MD/PhD
Phone: 508-653-3335 ext. 206
Email: michail.pankratov@corindus.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Kingsport, Tennessee 37660
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|